GO
Loading...

Anemia Drugs Under Attack

Friday, 11 May 2007 | 9:10 AM ET

Several investment banks slashed their ratings on Amgen shares, following the disclosure that a U.S. advisory panel called for marketing restrictions on popular anemia drugs sold by Amgen and J&J. Mike Huckman, CNBC pharmaceuticals reporter, has the details.